I may have missed this on the RVX Agoracom Board - has anyone discussed the similarities and differences of the mechanismof action of these two drugs on the board?

I recently watched a 60 minutes segment on Alzheimers which cited a research study in South America identifying a town in Puru or Chile I believe where many of the inhabitants had early Alzheimers onset. After studying their DNA, they could identify and predict those suceptible to early Alzheimers.   

Merck recently had a similar announcement on Verubecestat - "which blocks the enzyme BACE1, which pays a key role in the production of two molecules that link together to form the amyloid plaque. It is noted that people with BACE1 gene mutation are resistant to Alzheimer's disease. 

However, this is not the first drug to target BACE1, since a number of attempts made earlier aimed at inhibiting the emzyme failed as a result of aside effects that included eye problems and liver toxitity. The clinical trial by Merck involving Verubecestat is the first large scale trial conducted for Alzheimer's by far and the drug is said to have fewer side effects than those tested. 

It is reported that the drug is being tested in 1,500 patients in very early stahges of Alzheimer's disease and 2,000 patients suffering from mild to moderate levels of dimentia.  The results of the first phase of these trial are expected to be out in July 2017.

People are excited, said John Hardy, neuroscientist at University College London who first reported the role of amyloid plaque in Alzheimer's disease."

Epigenetic research is getting more and more positive attention. and is now at the cusp of recognition as the next wave of blockbuster drugs. It appears that RVX has overcome the toxitiy and safety issues and is well positioned with its patents, trial data, multiple clinical trials in progress, blood bank ... to finally get these new drugs to market.

My question to the scientists, doctors and researchers on this board - Is it possible that RVX-208 would improve the function of Verubecestat similiar to it's synergy with Rosuvastatin? - 

"Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor, inhibits BRD4, thereby regulating the expression of genes and restoring the function of pathways underlying the pathogenesis of CVD " - See Slide 16 Biotech Showcase 1/9/2017.

This was a wonderful way to start out the week - 

Chicagoest